PMID- 38162657
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240401
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - The role of immune checkpoints in antitumor response: a potential antitumor 
      immunotherapy.
PG  - 1298571
LID - 10.3389/fimmu.2023.1298571 [doi]
LID - 1298571
AB  - Immunotherapy aims to stimulate the immune system to inhibit tumor growth or 
      prevent metastases. Tumor cells primarily employ altered expression of human 
      leukocyte antigen (HLA) as a mechanism to avoid immune recognition and antitumor 
      immune response. The antitumor immune response is primarily mediated by CD8+ 
      cytotoxic T cells (CTLs) and natural killer (NK) cells, which plays a key role in 
      the overall anti-tumor immune response. It is crucial to comprehend the molecular 
      events occurring during the activation and subsequent regulation of these cell 
      populations. The interaction between antigenic peptides presented on HLA-I 
      molecules and the T-cell receptor (TCR) constitutes the initial signal required 
      for T cell activation. Once activated, in physiologic circumstances, immune 
      checkpoint expression by T cells suppress T cell effector functions when the 
      antigen is removed, to ensures the maintenance of self-tolerance, immune 
      homeostasis, and prevention of autoimmunity. However, in cancer, the 
      overexpression of these molecules represents a common method through which tumor 
      cells evade immune surveillance. Numerous therapeutic antibodies have been 
      developed to inhibit immune checkpoints, demonstrating antitumor activity with 
      fewer side effects compared to traditional chemotherapy. Nevertheless, it's worth 
      noting that many immune checkpoint expressions occur after T cell activation and 
      consequently, altered HLA expression on tumor cells could diminish the clinical 
      efficacy of these antibodies. This review provides an in-depth exploration of 
      immune checkpoint molecules, their corresponding blocking antibodies, and their 
      clinical applications.
CI  - Copyright (c) 2023 Mejia-Guarnizo, Monroy-Camacho, Turizo-Smith and 
      Rodriguez-Garcia.
FAU - Mejia-Guarnizo, Lidy Vannessa
AU  - Mejia-Guarnizo LV
AD  - Cancer Biology Research Group, Instituto Nacional de Cancerologia, Bogota, 
      Colombia.
AD  - Sciences Faculty, Master in Microbiology, Universidad Nacional de Colombia, 
      Bogota, Colombia.
FAU - Monroy-Camacho, Paula Stefany
AU  - Monroy-Camacho PS
AD  - Cancer Biology Research Group, Instituto Nacional de Cancerologia, Bogota, 
      Colombia.
FAU - Turizo-Smith, Andres David
AU  - Turizo-Smith AD
AD  - Medicine Faculty, Universidad Nacional de Colombia, Bogota, Colombia.
FAU - Rodriguez-Garcia, Josefa Antonia
AU  - Rodriguez-Garcia JA
AD  - Cancer Biology Research Group, Instituto Nacional de Cancerologia, Bogota, 
      Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231215
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - *Neoplasms
MH  - T-Lymphocytes, Cytotoxic
MH  - Immunotherapy/methods
MH  - Killer Cells, Natural
MH  - Antibodies
MH  - Histocompatibility Antigens Class I
MH  - HLA Antigens
PMC - PMC10757365
OTO - NOTNLM
OT  - HLA antigens
OT  - immune checkpoint inhibitors
OT  - immune evasion
OT  - immunotherapy
OT  - neoplasms
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/02 11:43
MHDA- 2024/01/03 09:44
PMCR- 2023/01/01
CRDT- 2024/01/01 04:27
PHST- 2023/09/21 00:00 [received]
PHST- 2023/11/29 00:00 [accepted]
PHST- 2024/01/03 09:44 [medline]
PHST- 2024/01/02 11:43 [pubmed]
PHST- 2024/01/01 04:27 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1298571 [doi]
PST - epublish
SO  - Front Immunol. 2023 Dec 15;14:1298571. doi: 10.3389/fimmu.2023.1298571. 
      eCollection 2023.